A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).
Carcinoma, Hepatocellular
DRUG: Relatlimab|DRUG: Nivolumab|DRUG: Bevacizumab|OTHER: Placebo
Incidence of dose-limiting toxicities (DLTs), Up to 6 weeks|Overall Response Rate (ORR) by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Assessed up to 3 years
Progression Free Survival (PFS) by BICR per RECIST v1.1 in all randomized participants that are lymphocyte activation gene 3 (LAG-3) positive, Assessed up to 3 years|PFS by BICR per RECIST v1.1 in all randomized participants, Assessed up to 3 years|ORR by BICR per RECIST v1.1 in all randomized participants that are LAG-3 positive, Assessed up to 3 years|Overall Survival (OS) of all randomized participants, Assessed up to 3 years|OS of all randomized participants that are LAG-3 positive, Assessed up to 3 years|Number of participants with adverse events (AEs), Up to 135 days after participant's last dose
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).